What is INDP's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.39B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for INDP?

P/E (TTM) is n/a and 52-week range is $0.92 to $5.96 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s INDP figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for INDP?

The company profile lists net income (TTM) near $-877M, EPS (TTM) near $-7.75 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Indaptus Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in New York City, New York, US, 113.2M shares outstanding, ISIN US45339J2042 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Indaptus Therapeutics Inc

$INDP

Health Care · Biotechnology

IR Run Scenarios

$2.51

+5.91%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Indaptus Therapeutics, Inc. is a clinical biotechnology company. The company is headquartered in New York City, New York and currently employs 5 full-time employees. The company went IPO on 2012-09-07. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The firm's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

Employees

Website

indaptusrx.com/

IPO

2012-09-07

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)